Sugi Predict

Sugi Predict / Compounds / SCHEMBL5548772

SCHEMBL5548772

SCHEMBL5548772

COc1c(C(C)C)cccc1C(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 3/20 0.50
▸ GABRG2 P18507 2/20 0.50
▸ GABRB3 P28472 2/20 0.50
▸ GABRB2 P47870 2/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ CYP3A4 P08684 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ FAAH O00519 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ GABRB1 P18505 1/20 0.50
▸ PTGS1 P23219 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ HTR2C P28335 1/20 0.50
▸ GABRA5 P31644 1/20 0.50
▸ GABRA3 P34903 1/20 0.50
▸ HTR2B P41595 1/20 0.50
▸ GABRA2 P47869 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16957771 0.89 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL2737276 0.86 LMNA (0.43) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL683593 0.86 NFE2L2 (0.47) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL19236578 0.85 TSHR (0.47) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL618635 0.84 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL16372662 0.84 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL12781802 0.84 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL458285 0.84 GABRA1 (0.56) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL16961659 0.84 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRB2CYP1A2
SCHEMBL12806392 0.84 CYP1A2 (0.44) GABRA1GABRG2GABRB3GABRB2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119613238-A Preparation method of 2-bromo-1- (3, 5-diisopropyl- [1,1' -biphenyl ] -4-yl) -1H-benzo [ d ] imidazole 浙江凯普化工有限公司 2025-03-14 — — CN claimed
CN-115368218-B Method for preparing 4-diaryl methyl substituted phenol compound 湖南理工学院 2024-01-02 — — CN claimed
US-20230043872-A1 COMPOSITION FOR LIP PAIN RELIEF AND METHOD OF MAKING WYSCAVER MEGHAN (US) 2023-02-09 — — US claimed
CN-115368218-A Method for preparing 4-diaryl methyl substituted phenol compound 湖南理工学院 2022-11-22 — — CN claimed
EP-3568418-A2 BRIDGED BIS(INDENYL) TRANSITIONAL METAL COMPLEXES, PRODUCTION, AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2019-11-20 — — EP claimed
US-20180201630-A1 Bridged Bis(Indenyl) Transitional Metal Complexes, Production, and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2018-07-19 — — US claimed
WO-2018132247-A2 BRIDGED BIS(INDENYL) TRANSITIONAL METAL COMPLEXES, PRODUCTION, AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2018-07-19 — — WO claimed
CN-119613238-A Preparation method of 2-bromo-1- (3, 5-diisopropyl- [1,1' -biphenyl ] -4-yl) -1H-benzo [ d ] imidazole 浙江凯普化工有限公司 2025-03-14 — — CN disclosed
CN-119613238-A Preparation method of 2-bromo-1- (3, 5-diisopropyl- [1,1' -biphenyl ] -4-yl) -1H-benzo [ d ] imidazole 浙江凯普化工有限公司 2025-03-14 — — CN disclosed
CN-115368218-B Method for preparing 4-diaryl methyl substituted phenol compound 湖南理工学院 2024-01-02 — — CN disclosed
WO-2023241950-A1 MIXTURES OF COMPOUNDS HAVING IMPROVED SOLUBILITY FOR USE AS MARKERS BASF SE (DE) 2023-12-21 — — WO disclosed
CN-116211754-A Oregano essential oil compound with high embedding rate, high stability and anti-inflammatory and soothing effects, and preparation method and application thereof 云南贝泰妮生物科技集团股份有限公司 2023-06-06 — — CN disclosed
US-20230043872-A1 COMPOSITION FOR LIP PAIN RELIEF AND METHOD OF MAKING WYSCAVER MEGHAN (US) 2023-02-09 — — US disclosed
EP-1066257-A2 HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE Sugen, Inc. (US) 2001-01-10 — — EP disclosed
EP-1034184-A2 NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS The Regents of the University of California (US) 2000-09-13 — — EP disclosed
WO-1999048868-A9 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN INC (US) 2000-04-20 — — WO disclosed
WO-1999048868-A2 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN, INC. (US) 1999-09-30 — — WO disclosed
WO-1999026966-A2 NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-06-03 — — WO disclosed
EP-0873361-A2 NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-10-28 — — EP disclosed
WO-1997021993-A2 NUCLEAR RECEPTOR LIGANDS AND LIGAND BINDING DOMAINS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180201630-A1 Bridged Bis(Indenyl) Transitional Metal Complexes, Production, and Use Thereof PCBP1, PARG, PARN GABRA1 3293/4885GABRG2 3149/4885GABRB3 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.